
GIVE THE PERFECT GIFT
Erin Mills Town Centre Gift Cards are the perfect choice for your gift giving needs.Purchase gift cards at kiosks near the food court or centre court, at Guest Services, or click below to purchase online.PURCHASE HEREHome
How To Control The Tuberculosis And HIV/AIDS Dual Epidemic
Indigo
Loading Inventory...
How To Control The Tuberculosis And HIV/AIDS Dual Epidemic
Current price: $50.50


How To Control The Tuberculosis And HIV/AIDS Dual Epidemic
Current price: $50.50
Loading Inventory...
Size: Paperback
*Product information may vary - to confirm product availability, pricing, shipping and return information please contact Indigo
TB patients can be offered an HIV test; indeed, research shows that TB patients are more likely to accept HIV testing than the general population. This means that TB programmes can make a major contribution to identifying eligible candidates for ARV treatment. Many people, including those living with HIV, do not know that TB is curable. This is a basic message and one thing that is failing to get through. We should know how to get the message to policy- makers and funders that more drugs are needed for both diseases. It is not "either/or', there is no point providing ARVs only for patients to die of TB for lack of TB resources. Similarly, TB efforts alone are insufficient. HIV/AIDS is dramatically fuelling the TB epidemic in sub-Saharan Africa, where up to 70% of TB patients are co-infected with HIV in some countries. For many years efforts to tackle TB and HIV have been largely separate, despite the overlapping epidemiology. Improved collaboration between TB and HIV/AIDS programmes will lead to more effective control of TB among HIV- infected people and to significant public health gains.
TB patients can be offered an HIV test; indeed, research shows that TB patients are more likely to accept HIV testing than the general population. This means that TB programmes can make a major contribution to identifying eligible candidates for ARV treatment. Many people, including those living with HIV, do not know that TB is curable. This is a basic message and one thing that is failing to get through. We should know how to get the message to policy- makers and funders that more drugs are needed for both diseases. It is not "either/or', there is no point providing ARVs only for patients to die of TB for lack of TB resources. Similarly, TB efforts alone are insufficient. HIV/AIDS is dramatically fuelling the TB epidemic in sub-Saharan Africa, where up to 70% of TB patients are co-infected with HIV in some countries. For many years efforts to tackle TB and HIV have been largely separate, despite the overlapping epidemiology. Improved collaboration between TB and HIV/AIDS programmes will lead to more effective control of TB among HIV- infected people and to significant public health gains.


















